Cargando…

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation

The entity myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome is characterized by the coexistence of both myeloproliferative and myelodysplastic features in the bone marrow. Risk assessment and treatment recommendations have not been standardized, and clinicians rely on updated pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hemsing, Anette Lodvir, Gjertsen, Bjørn Tore, Spetalen, Signe, Helgeland, Lars, Reikvam, Håkon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841861/ https://www.ncbi.nlm.nih.gov/pubmed/33628448 http://dx.doi.org/10.1177/2050313X20988413

Ejemplares similares

Mondor’s disease after extensive training with Nordic walking
por: Hemsing, Anette Lodvir, et al.
Publicado: (2019)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review
por: Wiese-Hansen, Hanne, et al.
Publicado: (2021)

NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition
por: Hemsing, Anette Lodvir, et al.
Publicado: (2022)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

PB1789: RAC1 INHIBITION IS FEASIBLE AND AFFECTS CELL MIGRATION IN A ZEBRAFISH LARVAE MODEL OF AML, INVESTIGATED USING A SOFTWARE TOOL FOR SINGLE-CELL VISUALIZATION
por: Hemsing, Anette Lodvir, et al.
Publicado: (2023)

Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
por: Hoshino, Yoshitomo, et al.
Publicado: (2023)

Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment
por: Hansen, Bent-Are, et al.
Publicado: (2019)

Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition
por: Brattås, Marte Karen, et al.
Publicado: (2022)

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
por: Luo, Shuna, et al.
Publicado: (2020)

Severe nephritis as initial sign of Waldenström’s macroglobulinemia
por: Knoop, Thomas, et al.
Publicado: (2019)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review
por: Zhao, Meifang, et al.
Publicado: (2021)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Co-occurrence of unclassified myeloproliferative neoplasm and giant cell arteritis in a patient treated with allogeneic hematopoietic stem cell transplantation: a case report and literature review
por: Bogucka-Fedorczuk, Aleksandra, et al.
Publicado: (2021)

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia
por: Jekarl, Dong Wook, et al.
Publicado: (2010)

Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53
por: Wang, Qian, et al.
Publicado: (2020)

Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms
por: WU, HUANLING, et al.
Publicado: (2013)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Limbic Encephalitis following Allogeneic Hematopoietic Stem Cell Transplantation
por: Johansen, Silje, et al.
Publicado: (2022)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases
por: Pizzi, Marco, et al.
Publicado: (2021)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2018)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
por: Hochman, Michael J., et al.
Publicado: (2021)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
por: Ichimura, Shinya, et al.
Publicado: (2012)

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
por: Clara, Joseph A., et al.
Publicado: (2016)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
por: Gerke, Margo B., et al.
Publicado: (2023)

A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation
por: Villafuerte-Gutiérrez, Paola, et al.
Publicado: (2018)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Brune, Magdalena M., et al.
Publicado: (2021)

MicroRNA serum profiles and chronic graft-versus-host disease
por: Reikvam, Håkon, et al.
Publicado: (2022)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
por: Jain, Tania, et al.
Publicado: (2023)

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Inherited myeloproliferative neoplasm risk impacts hematopoietic stem cells
por: Bao, Erik L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nucah5t90q57sbsn8uhqj9ob5b